Are ticagrelor and prasugrel an alternative in the antiplatelet treatment of ischemic stroke? YES


Published in: Cesk Slov Neurol N 2019; 82(6): 613
Category: Controversions


Sources

1. Kubica A, Kozinski M, Grezsk G et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011; 32(4): 459–466. doi: 10.1007/ s11239-011-0611-8.

2. Kastrati A. New anti-platelet agents: the end of resistance? Thromb Res 2012; 130 (Suppl 1): S53–S55. doi: 10.1016/ j.thromres.2012.08.275.

3. Johnston CB, Amarenco P, Albers GW et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375(1): 35–43. doi: 10.1056/ NEJMoa1603060

4. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001–2015. doi: 10.1056/ NEJMoa0706482.

5. Ogawa A, Toyoda K, Kitagawa K et al. Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I). Lancet Neurol 2019; 18(3): 238–247. doi: 10.1016/ S1474-4422(18)30449-6.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 6

2019 Issue 6

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account